|
|
|
Volumn 39, Issue 7, 1998, Pages
|
|
Future of nuclear medicine part 3: Assessment of the U.S. Therapeutic radiopharmaceuticals market (2001-2020)
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BISMUTH;
DYSPROSIUM;
IODINE 131;
IRIDIUM 192;
PHOSPHORUS 32;
RADIOPHARMACEUTICAL AGENT;
RADIUM;
RHENIUM 186;
RHENIUM 188;
SAMARIUM 153;
STRONTIUM 89;
TIN;
YTTRIUM 90;
BONE PAIN;
CANCER PAIN;
CANCER PALLIATIVE THERAPY;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HYPERTHYROIDISM;
MEDICAL RESEARCH;
NOTE;
NUCLEAR MEDICINE;
POLYCYTHEMIA VERA;
PRIORITY JOURNAL;
RADIOISOTOPE THERAPY;
THYROID CANCER;
UNITED STATES;
FORECASTING;
HUMANS;
NUCLEAR MEDICINE;
RADIOPHARMACEUTICALS;
UNITED STATES;
|
|
EID: 0031815956
PISSN: 01615505
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|